Eli Lilly and Company News - February 23, 2026
Eli Lilly Shares Surge as Novo Nordisk Weight-Loss Trial Fails
Eli Lilly (LLY) shares surged 4.84% to close at $1058.39 following a clinical setback for competitor Novo Nordisk and the official launch of the Zepbound...
🟢 LLY is trading 3.16% up today after Mounjaro outperforms Novo Nordisk's CagriSema in head-to-head trial
LLY is trading at $1041.44 (+3.16%) after its obesity drug Mounjaro outperformed Novo Nordisk's CagriSema in a head-to-head Phase 3 trial. • The study...
🟢 LLY is trading 2.72% up today as Mounjaro outperforms Novo Nordisk's CagriSema in head-to-head study
LLY is trading at $1037.00 (+2.72%) in pre-market action after Eli Lilly's Mounjaro outperformed Novo Nordisk's rival drug CagriSema in a head-to-head clinical...